On June 8, Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”) announced that its innovative anti-cancer drug, Chidamide tablets, had been officially designated a “Breakthrough Therapy” by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The proposed indication is Chidamide in combination with Sintilimab and Bevacizumab for the treatment of advanced microsatellite stable or mismatch repair proficient (MSS/pMMR) colorectal cancer in patients who have failed two or more prior lines of standard therapy. The Phase III clinical trial application submitted earlier by Chipscreen Biosciences for Chidamide in combination with Sintilimab and Bevacizumab for advanced MSS/pMMR colorectal cancer patients who have failed two or more prior lines of standard therapy was officially accepted on May 10.